Biomechanical Computer Models

In the past decade computer models have become very popular in the field of biomechanics due to exponentially increasing computer power. Biomechanical computer models can roughly be subdivided into two groups: multi-body models and numerical models. The theoretical aspects of both modelling strategies will be introduced. However, the focus of this chapter lies on demonstrating the power and versatility of computer models in the field of biomechanics by presenting sophisticated finite element models of human body parts. Special attention is paid to explain the setup of individual models using medical scan data. In order to reach the goal of individualising the model a chain of tools including medical imaging, image acquisition and processing, mesh generation, material modelling and finite element simulation –possibly on parallel computer architectures- becomes necessary. The basic concepts of these tools are described and application results are presented. The chapter ends with a short outlook into the future of computer biomechanics

Cosmic ray records in Antarctic meteorites

The cosmogenic radionuclides Be(10), Al(26), and Mn(53) and noble gases were determined in more than 28 meteorites from Antarctica by nuclear analytical techniques and static mass spectrometry, respectively. The summarized results are listed. The concentrations of Al(26) and Mn(53) are normalized to the repective main target elements and given in dpm/kg Si sub eq and dpm/kg Fe. The errors stated include statistical as well as systematical errors. For noble gas concentrations estimated errors are 5% and for isotopic ratios 1.5%. Cosmic ray exposure ages T sub 21 were calculated by the noble gas concentrations and the terrestrial residence time (T) on the basis of the spallogenic nuclide Al(26). The suggested pairing of the LL6 chondrite RKPA 80238 and RKPA 80248 and the eucrites ALHA 76005 and ALHA 79017 is confirmed not only by the noble gas data but also by the concentrations of the spallation produced radionuclides. Futhermore, ALHA 80122, clasified as an H6 chondrite, has a noble gas pattern which suggest that this meteorite belongs to the ALHA 80111 shower

Cosmogenic rare gases and 10-Be in a cross section of Knyahinya

The concentrations of cosmogenic nuclides were studied as a function of shielding on samples from a cross section of the 293 kg main fragment of the L5 chondrite Knyahinya. The stone broke into two nearly symmetrical parts upon its fall in 1866. The planar cross section has diameters between 40 and 55 cm. He, Ne, and Ar were measured on about 20 samples by mass spectrometry and the 10-Be activities on aliquots of 10 selected samples were determined by AMS. The 10-Be data are presented and the abundances of spallogenic nuclides are compared with the model calculations reported by Reedy for spherical L chondrites. The 10-Be production rates in Knyahinya are shown versus the shielding parameter 22-Ne/21-Ne

From the HINDAS Project : Excitation Functions for Residual Nuclide Production by Proton-Induced Reactions

peer reviewe

Polarized Secretion of Drosophila EGFR Ligand from Photoreceptor Neurons Is Controlled by ER Localization of the Ligand-Processing Machinery

Trafficking within the endoplasmic reticulum and specialized localization of the intra-membrane protease Rhomboid regulate EGF ligand-dependent signaling in Drosophila photoreceptor axon termini

WSES guidelines for management of Clostridium difficile infection in surgical patients

In the last two decades there have been dramatic changes in the epidemiology of Clostridium difficile infection (CDI), with increases in incidence and severity of disease in many countries worldwide. The incidence of CDI has also increased in surgical patients. Optimization of management of C difficile, has therefore become increasingly urgent. An international multidisciplinary panel of experts prepared evidenced-based World Society of Emergency Surgery (WSES) guidelines for management of CDI in surgical patients.Peer reviewe

Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study

Ristola M. on työryhmien DAD Study Grp ; Royal Free Hosp Clin Cohort ; INSIGHT Study Grp ; SMART Study Grp ; ESPRIT Study Grp jäsen.Background Chronic kidney disease (CKD) is a major health issue for HIV-positive individuals, associated with increased morbidity and mortality. Development and implementation of a risk score model for CKD would allow comparison of the risks and benefits of adding potentially nephrotoxic antiretrovirals to a treatment regimen and would identify those at greatest risk of CKD. The aims of this study were to develop a simple, externally validated, and widely applicable long-term risk score model for CKD in HIV-positive individuals that can guide decision making in clinical practice. Methods and Findings A total of 17,954 HIV-positive individuals from the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study with >= 3 estimated glomerular filtration rate (eGFR) values after 1 January 2004 were included. Baseline was defined as the first eGFR > 60 ml/min/1.73 m2 after 1 January 2004; individuals with exposure to tenofovir, atazanavir, atazanavir/ritonavir, lopinavir/ritonavir, other boosted protease inhibitors before baseline were excluded. CKD was defined as confirmed (>3 mo apart) eGFR In the D:A:D study, 641 individuals developed CKD during 103,185 person-years of follow-up (PYFU; incidence 6.2/1,000 PYFU, 95% CI 5.7-6.7; median follow-up 6.1 y, range 0.3-9.1 y). Older age, intravenous drug use, hepatitis C coinfection, lower baseline eGFR, female gender, lower CD4 count nadir, hypertension, diabetes, and cardiovascular disease (CVD) predicted CKD. The adjusted incidence rate ratios of these nine categorical variables were scaled and summed to create the risk score. The median risk score at baseline was -2 (interquartile range -4 to 2). There was a 1: 393 chance of developing CKD in the next 5 y in the low risk group (risk score = 5, 505 events), respectively. Number needed to harm (NNTH) at 5 y when starting unboosted atazanavir or lopinavir/ritonavir among those with a low risk score was 1,702 (95% CI 1,166-3,367); NNTH was 202 (95% CI 159-278) and 21 (95% CI 19-23), respectively, for those with a medium and high risk score. NNTH was 739 (95% CI 506-1462), 88 (95% CI 69-121), and 9 (95% CI 8-10) for those with a low, medium, and high risk score, respectively, starting tenofovir, atazanavir/ritonavir, or another boosted protease inhibitor. The Royal Free Hospital Clinic Cohort included 2,548 individuals, of whom 94 individuals developed CKD (3.7%) during 18,376 PYFU (median follow-up 7.4 y, range 0.3-12.7 y). Of 2,013 individuals included from the SMART/ESPRIT control arms, 32 individuals developed CKD (1.6%) during 8,452 PYFU (median follow-up 4.1 y, range 0.6-8.1 y). External validation showed that the risk score predicted well in these cohorts. Limitations of this study included limited data on race and no information on proteinuria. Conclusions Both traditional and HIV-related risk factors were predictive of CKD. These factors were used to develop a risk score for CKD in HIV infection, externally validated, that has direct clinical relevance for patients and clinicians to weigh the benefits of certain antiretrovirals against the risk of CKD and to identify those at greatest risk of CKD.Peer reviewe